Pharmacodynamic Study of dexmedetomidine sedation in children for transthoracic echocardiography examination

Median effective dose of intranasal dexmedetomidine sedation for transthoracic echocardiography examination in cyanotic and noncyanotic congenital heart disease children: an up-and-down sequential allocation trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPC-17012983

Enrollment

Unknown

Registered

2017-10-14

Start date

2017-10-22

Completion date

Unknown

Last updated

2017-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

congenital cardiovascular disease

Interventions

1:dexmedetomidine1ug/Kg~4ug/Kg

Eligibility

Sex/Gender

All

Age

No minimum to 2 Years

Inclusion criteria

Inclusion criteria: children aged 0 to 24 months old, with Congenital heart disease and to be classified as American Society of Anesthesiologists physical status I or Iv.

Exclusion criteria

Exclusion criteria: 1. known allergy to dexmedetomidine; 2. recent treatment with a-2 adrenergic receptor agonist; 3. renal or hepatic dysfunction; 4. nasal discharges; 5. history of preterm birth.

Design outcomes

Primary

Measure	Time frame
heart rate;	—

Countries

china

Contacts

Public ContactShengfen Tu

Children's Hospital of Chongqing Medical University

519194496@qq.com+86 13983416114

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026